Summary

Rare Kidney Diseases Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Target Disease Indications (Atypical Hemolytic Uremic Syndrome, Fabry Disease, Immunoglobulin A Nephropathy, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney Disease, Lupus Nephritis and Others), Type of Molecule (Small Molecules and Biologics), Type of Biologics (Monoclonal Antibodies and Proteins), Route of Administration (Oral, Intravenous, Subcutaneous, and Others), Type of Therapy (Monotherapy, Combination Therapy), Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World), Leading Drug Developers and Sales Forecast
Report Link: https://www.rootsanalysis.com/reports/rare-kidney-diseases-market.html
The Rare Kidney Diseases Market is expected to reach 3.9 billion in 2024 anticipated to grow at a CAGR of 11% during the forecast period 2024-2035.

Rare kidney diseases encompass a wide array of conditions, covering at least 150 distinct disorders. In Europe, a condition is classified as rare if its prevalence is below 1 in 2000 individuals, while in the US, it's considered rare if it affects fewer than 200,000 people. Notably, in 2020, despite an alarming need, only 500 out of over 8,000 individuals diagnosed with rare kidney diseases received treatment. Research indicates that over 12% of individuals with kidney failure suffer from rare kidney diseases, leading to chronic debilitation and morbidity. Consequently, various stakeholders in this field have initiated various efforts to advance tailored therapeutics for these conditions. Since 2019, approximately USD 8 billion has been invested in companies dedicated to developing therapies for rare kidney diseases. However, progress in diagnosis and treatment has been hindered by factors such as limited patient populations, the absence of prognostic biomarkers, clinical diversity, and inadequate model organisms. Notable strides have been made to address these challenges.

The emergence of precision medicine, including genomic sequencing and personalized therapies, has facilitated targeted interventions for rare kidney diseases. Drug repurposing, which involves identifying new therapeutic targets and leveraging the pharmacological properties of existing drugs, has emerged as a cost-effective strategy. Additionally, the integration of artificial intelligence (AI) and machine learning algorithms to optimize personalized treatment represents a prominent technological advancement. Recently, several drugs targeting various indications of rare kidney diseases have received approval from regulatory authorities worldwide. In 2023, the Food and Drug Administration (FDA) approved Elfabrio (developed by Protalix BioTherapeutics) for Fabry Disease and Tarpeyo (developed by Calliditas Therapeutics) for IgA Nephropathy. With the promising prospects associated with these drugs, both private and public investors have directed their attention towards the rare kidney diseases market, fueling substantial growth during the forecast period.

Research Coverage:
A detailed assessment of current market landscape considering the rare kidney diseases, accounting for various parameters, including the year of establishment, company size (based on the employee count), location of headquarters, phase of development (discovery to marketed), route of administration (oral, intravenous, subcutaneous, and others), type of molecule (biologics and small molecules), subtype of biologics (monoclonal antibodies, proteins, cell and gene therapies, RNA, biosimilars, stem cells, and live biotherapeutic products), dosing frequency (single dose, multiple dose, combination), type of therapy (monotherapy and combination therapy), target patient population (children, adults, and elderly patients), and target indication (Lupus Nephritis, Immunoglobulin A, Nephropathy, Focal Segmental Glomerulosclerosis, Membranous Nephropathy, Fabry Disease, Autosomal Polycystic Kidney Disease, Nephrotic Syndrome, Alport Syndrome, Atypical Hemolytic Uremic Syndrome, and C3 Glomerulopathy).
Comprehensive company profiles of key players (shortlisted based on the diversity of their drug portfolios) operating in the rare kidney diseases market. Each profile presents the company overview, financial information, rare kidney disease portfolio specifics, recent advancements, and an insightful projection for the future.
Concise profiles of leading players (shortlisted based on their robust drug portfolios) operating in the rare kidney diseases market. Each profile highlights a concise overview of the company (year of establishment, employee count, location of headquarters, and leadership team) and financial information (if available).
A detailed assessment of company competitiveness among key developers in the rare kidney diseases domain, considering various pertinent parameters. These include supplier robustness (evaluated by years of experience and company size), company competitiveness (assessed by the most advanced drug development phase, quantity of drugs developed, route of administration, and molecule type), and the breadth of indications targeted by each drug.
A detailed examination of the partnerships and collaborations signed among the stakeholders involved in this sector since 2019, encompassing the licensing agreements, research and development collaborations, mergers and acquisitions, product development partnerships, commercialization agreements, distribution partnerships, joint ventures, supply agreements, service agreements, technology utilization agreements, process development agreements, and other pertinent arrangements.
An assessment of funding and investment analysis directed towards the key companies focusing on the rare kidney disease treatments, spanning venture capital investments, funds raised through initial public offerings (IPOs) and subsequent offerings, grants, private placements, as well as equity and debt financing. This analysis delves into the funding occurrences from 2019 to 2023, shedding light on the increasing attention from the venture capital community and other strategic investors within this market.
A detailed assessment of both active and ongoing clinical trials concerning the therapies for rare kidney diseases, focusing on various pertinent factors including the year of trial registration, trial status, trial phase, study design (masking type, intervention model type, and primary purpose), type of sponsor, the most active industry and non-industry players (based on trial count), geographical distribution, and the enrolled patient populations.
A comprehensive analysis of the clinical and commercial demand of therapeutics focused on treating rare kidney disorders, considering multiple relevant factors such as the size of the target patient population, dosing frequency, and the strength of doses.
A thorough analysis of the key opinion leaders (KOLs) engaged in the conduct of clinical trials associated with rare kidney diseases, considering various pertinent factors including type of KOL, affiliated organization, targeted disease indication, industry and non-industry affiliations, as well as the geographical distribution of KOLs. Moreover, the section emphasizes the most active KOLs, evaluated through both our proprietary and third-party scoring methodologies.
A case study presenting insights on the enterprises providing kidney care services, including details such as their year of establishment, company size employee count), location of headquarters, and focus on specific medical conditions.
A comprehensive analysis of the recent expansions of the rare kidney diseases market, encompassing the identification and evaluation of primary catalysts, potential obstacles, emerging prospects, and prevailing hurdles.
A detailed analysis of the present market size, current opportunities within rare kidney diseases therapies, and the prospective growth trajectory of the rare kidney diseases market over the next decade. Drawing on various parameters including anticipated adoption trends and validated primary data, we've formulated an informed projection of market evolution till 2035. Detailed projections of the current and future market for rare kidney disease therapeutics across types of target indications, such as Atypical Hemolytic Uremic Syndrome, Fabry Disease, Immunoglobulin A Nephropathy, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney Disease, Lupus Nephritis and others.
Detailed predictions of the current and future rare kidney disease market based on type of molecule, such as small molecules and biologics.
Comprehensive projections of the current and future rare kidney diseases market based on the type of biologics, such as monoclonal antibodies and proteins.
Comprehensive projections of the current and future rare kidney disease market based on the types of routes of administration, such as oral, intravenous, subcutaneous, and others.
Detailed predictions of the current and future rare kidney diseases market across types of therapy, such as monotherapy and combination therapy.
Comprehensive projections of the current and future rare kidney diseases industry across key geographical regions, such as North America, Europe, Asia-Pacific and the rest of the world.
Detailed projections of the current and future rare kidney disease market across the sales of forecasted drugs.
Comprehensive projections of the current and future revenues from the sales of around 20 top-selling drugs developed by the leading players in the rare kidney diseases market, including Alexion Pharmaceuticals, Amicus Therapeutics, Aurinia Pharmaceuticals, GSK, Otsuka Pharmaceutical and other players.
Key Benefits of Buying this Report
The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
The report provides stakeholders with a pulse on the Rare Kidney Diseases Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
Leading Market Companies
Alexion Pharmaceuticals
Chinook Therapeutics
Horizon Therapeutics
Jiangsu Hengrui Pharmaceuticals
Novartis
Omeros
Roche
Sanofi
Travere Therapeutics
ZyVersa Therapeutics
Advicenne
Apellis Pharmaceuticals
argenx
Astellas Pharma
Boehringer Ingelheim
Calliditas Therapeutics
GSK
Mallinckrodt Pharmaceuticals
Synlogic
Takeda

ページTOPに戻る

Table of Contents

1. RESEARCH METHODOLOGY

2. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3. EXECUTIVE SUMMARY

4. INTRODUCTION
4.1. Overview of Kidney Diseases
4.1.1. Key Historical Events related to Kidney Diseases
4.1.2. Factors Contributing to Kidney Diseases

4.2. Overview of Rare Kidney Diseases
4.2.1. Types of Rare Kidney Diseases
4.2.2. Challenges Associated with RKD Diagnosis and Treatment

4.3. Selection of Therapeutic targets for Rare Kidney Diseases
4.4. Technological Advancements in the Rare Kidney Diseases Domain
4.5. Recent Developments in the Rare Kidney Diseases Domain
4.6. Future Perspectives

5. MARKET LANDSCAPE
5.1. Rare Kidney Disease Therapies: Market Landscape
5.1.1. Analysis by Phase of Development
5.1.2. Analysis by Route of Administration
5.1.3. Analysis by Type Molecule
5.1.4. Analysis by Target Disease Indication
5.1.5. Analysis by Type of Biologic
5.1.6. Analysis by Type of Therapy
5.1.7. Analysis by Dosing Frequency
5.1.8. Analysis by Target Patient Segment
5.1.9. Key Facts on Drug Designation

6. RARE KIDNEY DISEASE THERAPIES: DETAILED COMPANY PROFILES
6.1. Chapter Overview
6.1.1. Alexion Pharmaceuticals
6.1.1.1 Company Overview
6.1.1.2 Financial Information
6.1.1.3 Pipeline Portfolio
6.1.1.4 Recent Developments and Future Outlook

6.1.2. Chinook Therapeutics
6.1.2.1 Company Overview
6.1.2.2 Financial Information
6.1.2.3 Pipeline Portfolio
6.1.2.4 Recent Developments and Future Outlook

6.1.3. Horizon Therapeutics
6.1.3.1 Company Overview
6.1.3.2 Financial Information
6.1.3.3 Pipeline Portfolio
6.1.3.4 Recent Developments and Future Outlook

6.1.4. Jiangsu Hengrui Pharmaceuticals
6.1.4.1 Company Overview
6.1.4.2 Financial Information
6.1.4.3 Pipeline Portfolio
6.1.4.4 Recent Developments and Future Outlook

6.1.5. Novartis
6.1.5.1 Company Overview
6.1.5.2 Financial Information
6.1.5.3 Pipeline Portfolio
6.1.5.4 Recent Developments and Future Outlook

6.1.6. Omeros
6.1.6.1 Company Overview
6.1.6.2 Financial Information
6.1.6.3 Pipeline Portfolio
6.1.6.4 Recent Developments and Future Outlook

6.1.7. Roche
6.1.7.1 Company Overview
6.1.7.2 Financial Information
6.1.7.3 Pipeline Portfolio
6.1.7.4 Recent Developments and Future Outlook

6.1.8. Sanofi
6.1.8.1 Company Overview
6.1.8.2 Financial Information
6.1.8.3 Pipeline Portfolio
6.1.8.4 Recent Developments and Future Outlook

6.1.9. Travere Therapeutics
6.1.9.1 Company Overview
6.1.9.2 Financial Information
6.1.9.3 Pipeline Portfolio
6.1.9.4 Recent Developments and Future Outlook

6.1.10. ZyVersa Therapeutics
6.1.10.1 Company Overview
6.1.10.2 Financial Information
6.1.10.3 Pipeline Portfolio
6.1.10.4 Recent Developments and Future Outlook

7. RARE KIDNEY DISEASE THERAPIES: SHORT COMPANY PROFILES
7.1. Chapter Overview
7.1.1 Advicenne
7.1.1.1 Company Overview
7.1.1.2. Pipeline Portfolio

7.1.2. Apellis Pharmaceuticals
7.1.2.1 Company Overview
7.1.2.2. Pipeline Portfolio

7.1.3. argenx
7.1.3.1 Company Overview
7.1.3.2. Pipeline Portfolio

7.1.4. Astellas Pharma
7.1.4.1 Company Overview
7.1.4.2. Pipeline Portfolio

7.1.5. Boehringer Ingelheim
7.1.5.1 Company Overview
7.1.5.2. Pipeline Portfolio

7.1.6. Calliditas Therapeutics
7.1.6.1 Company Overview
7.1.6.2. Pipeline Portfolio

7.1.7. GSK
7.1.7.1 Company Overview
7.1.7.2. Pipeline Portfolio

7.1.8. Mallinckrodt Pharmaceuticals
7.1.8.1 Company Overview
7.1.8.2. Pipeline Portfolio

7.1.9. Synlogic
7.1.9.1 Company Overview
7.1.9.2. Pipeline Portfolio

7.1.10. Takeda
7.1.10.1 Company Overview
7.1.10.2. Pipeline Portfolio

8. COMPANY COMPETITIVENESS ANALYSIS
8.1 Key Parameters and Scoring Criteria
8.2. Analysis Methodology
8.3. Rare Kidney Disease Therapies Developers: Company Competitiveness Analysis
8.3.1. Rare Kidney Disease Therapies Developers based in North America (Peer Group I)
8.3.2. Rare Kidney Disease Therapies Developers based in Europe (Peer Group II)
8.3.3. Rare Kidney Disease Therapies Developers based in Asia-Pacific and Rest of the World (Peer Group III)

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Rare Kidney Disease Therapies: Partnerships and Collaborations
9.3.1 Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Target Disease Indication
9.3.5. Analysis by Type of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships

9.3.7. Analysis by Geography
9.3.7.1. Local and International Deals
9.3.7.2. Intercontinental and Intracontinental Deals

10. FUNDING AND INVESTMENTS
10.1. Chapter Overview
10.2. Types of Funding
10.3. Rare Kidney Disease Therapies: Funding and Investments
10.3.1. Analysis by Year of Investment
10.3.2. Analysis by Amount Invested
10.3.3. Analysis by Type of Funding
10.3.4. Analysis of Amount Invested by Type of Funding
10.3.5. Analysis of Amount Invested by Year and Type of Funding
10.3.6. Analysis by Target Disease Indication
10.3.7. Analysis by Geography
10.3.8. Most Active Players: Analysis by Number of Instances
10.3.9. Most Active Players: Analysis by Amount Invested
10.3.10. Leading Investors: Analysis by Number of Instances

11. CLINICAL TRIAL ANALYSIS
11.1. Analysis Methodology and Key Parameters
11.2. Rare Kidney Disease Therapies: Clinical Trial Analysis
11.2.1. Analysis by Trial Registration Year
11.2.2. Analysis by Trial Status
11.2.3. Analysis by Trial Registration Year and Trial Status
11.2.4. Analysis by Trial Registration Year and Patients Enrolled
11.2.5. Analysis by Trial Status and Patients Enrolled
11.2.6. Analysis by Trial Phase
11.2.7. Analysis by Study Design
11.2.8. Analysis by Trial Status, Trial Phase and Geography
11.2.9. Analysis by Type of Sponsor
11.2.10. Analysis by Gender of Patients
11.2.11. Most Active Industry Players: Analysis by Number of Trials
11.2.12. Most Active Non-Industry Players: Analysis by Number of Trials
11.2.13. Analysis by Geography

12. CLINICAL COMMERCIAL ATTRACTIVENESS
12.1. Methodology and Parameters
12.2. Key Parameters and Scoring
12.3. Clinical and Commercial Attractiveness Analysis: Phase III Drugs Targeting Rare Kidney Diseases

13. KEY OPINION LEADERS
13.1. Methodology and Key Parameters
13.2. Rare Kidney Disease Therapies: Key Opinion Leaders (KOLs)
13.2.1. Analysis by Type of KOL
13.2.2. Analysis by Type of Organization
13.2.3. Analysis by Target Disease Indication
13.2.4. Analysis by Industry Affiliated Organization
13.2.5. Analysis by Non-Industry Affiliated Organization
13.2.6. Analysis by Geographical Location of KOLs
13.2.7. Most Prominent KOLs: Peer Group 1 (Principal Investigators)
13.2.8. Most Prominent KOLs: Peer Group 2 (Study Directors)
13.2.9. Most Prominent KOLs: Peer Group 3 (Study Chairs)
13.2.10. Most Prominent KOLs: Analysis by RA Score

14. CASE STUDY
14.1. Scope and Key Parameters
14.2. Rare Kidney Disorders: List of Kidney Care Providers
14.3. Rare Kidney Disorders: Advantages of Kidney Care
14.4. Rare Kidney Disorders: Recent Developments

15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
15.1. Chapter Overview
15.2. Market Drivers
15.3. Market Restraints
15.4. Market Opportunities
15.5. Market Challenges
15.6. Conclusion

16. RARE KIDNEY DISEASE MARKET
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Assumptions for Phase III Rare Kidney Disease Drugs
16.4. Forecast Model

16.5. Global Rare Kidney Disease Market, Historical Trends and Forecasted Estimates, till 2035
16.5.1. Scenario Analysis

17. RARE KIDNEY DISEASE MARKET, BY TARGET DISEASE INDICATION
17.1. Chapter Overview
17.2. Rare Kidney Disease Market: Distribution by Target Disease Indication, 2024, 2030 and 2035
17.2.1. Rare Kidney Disease Market for Atypical Hemolytic Uremic Syndrome, till 2035
17.2.2. Rare Kidney Disease Market for Fabry Disease, till 2035
17.2.3. Rare Kidney Disease Market for Immunoglobulin A Nephropathy, till 2035
17.2.4. Rare Kidney Disease Market for Focal Segmental Glomerulosclerosis, till 2035
17.2.5. Rare Kidney Disease Market for Autosomal Dominant Polycystic Kidney Disease, till 2035
17.2.6. Rare Kidney Disease Market for Lupus Nephritis, till 2035
17.2.7. Rare Kidney Disease Market for Others, till 2035

18. RARE KIDNEY DISEASE MARKET, BY TYPE OF MOLECULE
18.1. Chapter Overview
18.2. Rare Kidney Disease Market: Distribution by Type of Molecule, 2024, 2030 and 2035
18.2.1. Rare Kidney Disease Market for Small Molecules, till 2035
18.2.2. Rare Kidney Disease Market for Biologics, till 2035

19. RARE KIDNEY DISEASE MARKET, BY TYPE OF BIOLOGICS
19.1. Chapter Overview
19.2. Rare Kidney Disease Market: Distribution by Type of Biologic, 2024, 2030 and 2035
19.2.1. Rare Kidney Disease Market for Monoclonal Antibodies, till 2035
19.2.2. Rare Kidney Disease Market for Proteins, till 2035

20. RARE KIDNEY DISEASE MARKET, BY ROUTE OF ADMINISTRATION
20.1. Chapter Overview
20.2. Rare Kidney Disease Market: Distribution by Route of Administration, 2024, 2030 and 2035
20.2.1. Rare Kidney Disease Market for Oral, till 2035
20.2.2. Rare Kidney Disease Market for Intravenous, till 2035
20.2.3. Rare Kidney Disease Market for Subcutaneous, till 2035
20.2.4. Rare Kidney Disease Market for Others, till 2035

21. RARE KIDNEY DISEASE MARKET, BY TYPE OF THERAPY
21.1. Chapter Overview
21.2. Rare Kidney Disease Market: Distribution by Type of Therapy, 2024, 2030 and 2035
21.2.1. Rare Kidney Disease Market for Monotherapy, till 2035
21.2.2. Rare Kidney Disease Market for Combination Therapy, till 2035

22. RARE KIDNEY DISEASE MARKET, BY GEOGRAPHY
22.1. Chapter Overview
22.2. Rare Kidney Disease Market: Distribution by Key Geographical Regions, 2024, 2030 and 2035
22.2.1. North America: Forecasted Estimates, till 2035
22.2.2. Europe: Forecasted Estimates, till 2035
22.2.3. Asia-Pacific: Forecasted Estimates, till 2035
22.3.4. Rest of the World: Forecasted Estimates, till 2035

23. RARE KIDNEY DISEASES MARKET, SALES FORECAST OF DRUGS
23.1. Chapter Overview
23.2. Approved Rare Kidney Disease Therapies Market: Sales Forecast
23.2.1. Agalsidase Beta BS I.V. Infusion / Agalsidase beta / JR-051 Sales Forecast
23.2.2. Benlysta® / Belimumab Sales Forecast
23.2.3. Elfabrio® / PRX-102 / Pegunigalsidase Alfa Sales Forecast
23.2.4. FILSPARI® / Sparsentan / RE-021 Sales Forecast
23.2.5. Galafold / Migalastat / AT1001 Sales Forecast
23.2.6. LUPKYNIS® / Voclosporin Sales Forecast
23.2.7. Sibnayal® / ADV7103 Sales Forecast
23.2.8. Tarpeyo® / Nef-301 / Nefigard-OLE / Nefecon / Kinpeygo Sales Forecast
23.2.9. TERLIVAZ® / Terlipressin Sales Forecast
23.2.10. Tolvaptan / Jynarque / Samsca / OPC-156 Sales Forecast
23.2.11. ULTOMIRIS® / Ravulizumab-cwvz Sales Forecast

23.3. Phase III Rare Kidney Disease Therapies Market: Sales Forecast
23.3.1. APL-2 / Pegcetacoplan/ Aspaveli / EMPAVELI / SYFOVRE Sales Forecast
23.3.2. Atacicept / VT-001 Sales Forecast
23.3.3. Atrasentan / CHK-01 / Atrasentan Hydrochloride / ABT-627 / Xinlay Sales Forecast
23.3.4. FILSPARI® / Sparsentan / RE-021 Sales Forecast
23.3.5. IONIS-FB-LRX / RO-7434656 / ASO Factor B / ISIS-696844 / RG6299 Sales Forecast
23.3.6. Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast
23.3.7. Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast
23.3.8. Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast
23.3.9. Lucerastat / ACT 434964 / OGT 923 Sales Forecast
23.3.10. MIL62 Sales Forecast
23.3.11. Obinutuzumab / Afutuzumab / GA101 / Gazyva / RO5072759 Sales Forecast
23.3.12. Obinutuzumab / Afutuzumab / GA101 / Gazyva / RO5072759 Sales Forecast
23.3.13. Repagermanium / DMX-200 Sales Forecast
23.3.14. Sibeprenlimab / VIS-649 Sales Forecast
23.3.15. SNP-ACTH / SNP ACTH (1-39) Sales Forecast
23.3.16. Telitacicept / RC18 Sales Forecast
23.3.17. Tolvaptan / Jynarque / Samsca / OPC-156 Sales Forecast
23.3.18. Venglustat / Ibiglustat / GZ402671 Sales Forecast

24. RARE KIDNEY DISEASES MARKET, BY LEADING DRUG DEVELOPERS
24.1. Chapter Overview
24.2. Rare Kidney Diseases Market: Distribution by Leading Drug Developers, 2024 (USD Million)
24.2. Rare Kidney Diseases Market: Distribution by Leading Drug Developers, 2035 (USD Million)

25. EXECUTIVE INSIGHTS
25.1. Chapter Overview
25.2. Company A
25.2.1. Company Snapshot
25.2.2. Interview Transcript: Chief Executive Officer

25.3. Chapter Overview
25.3. Company B
25.3.1. Company Snapshot
25.3.2. Interview Transcript: Associate BD Director

26 APPENDIX I: TABULATED DATA

27 APPENDIX I1: LIST OF COMPANIES AND ORGANIZATIONS

ページTOPに戻る

List of Tables/Graphs

Figure 1.1 Research Methodology: Project Methodology
Figure 1.2 Research Methodology: Forecast Methodology
Figure 3.1 Executive Summary: Overall Market Landscape
Figure 3.2 Executive Summary: Partnerships and Collaborations
Figure 3.3 Executive Summary: Funding and Investment Analysis
Figure 3.4 Executive Summary: Clinical Trial Analysis
Figure 3.5 Executive Summary: Key Opinion Leaders
Figure 3.6 Executive Summary: Market Sizing and Opportunity Analysis
Figure 4.1 Key Historical Events
Figure 4.2 Factors Contributing to Rare Kidney Disorders
Figure 4.3 Types of Rare Kidney Diseases
Figure 4.4 Challenges Associated with RKD Diagnosis and Treatment
Figure 4.5 Selection of Therapeutic Targets for Rare Kidney Diseases
Figure 4.6 Technological Advancements in Rare Kidney Diseases Domain
Figure 5.1 Rare Kidney Diseases: Distribution by Phase of Development
Figure 5.2 Rare Kidney Diseases: Distribution by Route of Administration
Figure 5.3 Rare Kidney Diseases: Distribution by Type Molecule
Figure 5.4 Rare Kidney Diseases: Distribution by Target Disease Indication
Figure 5.5 Rare Kidney Diseases: Distribution by Type of Biologic
Figure 5.6 Rare Kidney Diseases: Distribution by Type of Therapy
Figure 5.7 Rare Kidney Diseases: Distribution by Dosing Frequency
Figure 5.8 Rare Kidney Diseases: Distribution by Target Patient Segment
Figure 5.9 Rare Kidney Diseases: Key Facts on Drug Designation
Figure 5.10 Rare Kidney Diseases Developers: Distribution by Year of Establishment
Figure 5.11 Rare Kidney Diseases Developers: Distribution by Company Size
Figure 5.12 Rare Kidney Diseases Developers: Distribution by Location of Headquarters
Figure 5.13 Most Active Players: Distribution by Number of Therapies
Figure 6.1 AstraZeneca: Annual Revenues, FY 2018- FY 2023 (USD Billion)
Figure 6.2 Chinook Therapeutics: Annual Revenues, FY 2018- Q1 FY 2023 (USD Million)
Figure 6.3 Horizon Therapeutics: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Figure 6.4 Jiangsu Hengrui Pharmaceuticals: Annual Revenues, FY 2018-FY 2022 (CNY Million)
Figure 6.5 Novartis: Annual Revenues, FY 2018-FY 2023 (USD Billion)
Figure 6.6 Omeros: Annual Revenues, FY 2018-FY 2022 (USD Million)
Figure 6.7 Roche: Annual Revenues, FY 2018-FY 2023 (CHF Billion)
Figure 6.8 Sanofi: Annual Revenues, FY 2018-FY 2023 (EUR Billion)
Figure 6.9 Travere Therapeutics: Annual Revenue, FY 2018-9M FY 2023 (USD Million)
Figure 8.1 Company Competitiveness Analysis: Rare Kidney Disease Therapies Developers based in North America
Figure 8.2 Company Competitiveness Analysis: Rare Kidney Disease Therapies Developers based in Europe
Figure 8.3 Company Competitiveness Analysis: Rare Kidney Disease Therapies Developers based in Asia-Pacific and Rest of the World
Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Target Disease Indication
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.6 Most Active Players: Distribution by Number of Partnerships
Figure 9.7 Partnerships and Collaborations: Local and International Deals
Figure 9.8 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 10.1 Funding and Investments: Distribution by Year of Investment, 2019-2023
Figure 10.2 Funding and Investments: Distribution by Amount Invested (USD Million)
Figure 10.3 Funding and Investments: Distribution by Type of Funding
Figure 10.4 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 10.5 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding (USD Million)
Figure 10.6 Funding and Investments: Distribution by Target Disease Indication
Figure 10.7 Funding and Investments: Distribution by Geography
Figure 10.8 Most Active Players: Distribution by Number of Instances
Figure 10.9 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 10.10 Leading Investors: Distribution by Number of Instances
Figure 11.1 Clinical Trial Analysis: Cumulative Year-wise Trend, 2019-2023
Figure 11.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 11.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 11.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Figure 11.5 Clinical Trial Analysis: Distribution by Trial Status and Patients Enrolled
Figure 11.6 Clinical Trial Analysis: Distribution by Trial Phase
Figure 11.7 Clinical Trial Analysis: Distribution by Study Design
Figure 11.8 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography
Figure 11.9 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 11.10 Clinical Trial Analysis: Distribution by Gender of Patients
Figure 11.11 Most Active Industry Players: Analysis by Number of Trials
Figure 11.12 Most Active Non-Industry Players: Analysis by Number of Trials
Figure 11.13 Clinical Trial Analysis: Distribution by Geography and Trial Status (Number of Trials)
Figure 11.14 Clinical Trial Analysis: Distribution by Geography and Trial Status (Patients Enrolled)
Figure 12.1 Clinical and Commercial Attractiveness Analysis
Figure 13.1 Rare Kidney Disease Therapies KOL Analysis: Distribution by Type of KOL
Figure 13.2 Rare Kidney Disease Therapies KOL Analysis: Distribution by Type of Organization
Figure 13.3 Rare Kidney Disease Therapies KOL Analysis: Distribution by Target Disease Indication
Figure 13.4 Rare Kidney Disease Therapies KOL Analysis: Distribution by Industry Affiliated Organization
Figure 13.5 Rare Kidney Disease Therapies KOL Analysis: Distribution by Non-Industry Affiliated Organization
Figure 13.6 Rare Kidney Disease Therapies KOL Analysis: Geographical Distribution of KOLs
Figure 13.7 Most Prominent KOLs: Peer Group 1 (Principal Investigators)
Figure 13.8 Most Prominent KOLs: Peer Group 2 (Study Directors)
Figure 13.9 Most Prominent KOLs: Peer Group 3 (Study Chairs)
Figure 13.10 Most Prominent KOLs: Distribution by RA score
Figure 16.1 Global Rare Kidney Disease Market, Forecasted Estimates, till 2035, Base Scenario (USD Billion)
Figure 16.2 Global Rare Kidney Disease Market, Forecasted Estimates, till 2035, Conservative Scenario (USD Billion)
Figure 16.3 Global Rare Kidney Disease Market, Forecasted Estimates, till 2035, Optimistic Scenario (USD Billion)
Figure 17.1 Global Rare Kidney Disease Market: Distribution by Target Disease Indication, 2024, 2030 and 2035 (USD Billion)
Figure 17.2 Rare Kidney Disease Market for Atypical Hemolytic Uremic Syndrome, Forecasted Estimates, till 2035 (USD Billion)
Figure 17.3 Rare Kidney Disease Market for Fabry Disease, Forecasted Estimates, till 2035 (USD Billion)
Figure 17.4 Rare Kidney Disease Market for Immunoglobulin A Nephropathy, Forecasted Estimates, till 2035 (USD Billion)
Figure 17.5 Rare Kidney Disease Market for Focal Segmental Glomerulosclerosis, Forecasted Estimates, till 2035 (USD Billion)
Figure 17.6 Rare Kidney Disease Market for Autosomal Dominant Polycystic Kidney Disease, Forecasted Estimates, till 2035 (USD Billion)
Figure 17.7 Rare Kidney Disease Market for Lupus Nephritis, Forecasted Estimates, till 2035 (USD Billion)
Figure 17.8 Rare Kidney Disease Market for Others, Forecasted Estimates, till 2035 (USD Billion)
Figure 18.1 Global Rare Kidney Disease Market: Distribution by Type of Molecule, 2024, 2030 and 2035 (USD Billion)
Figure 18.2 Rare Kidney Disease Market for Small Molecules, Forecasted Estimates, till 2035 (USD Billion)
Figure 18.3 Rare Kidney Disease Market for Biologics, Forecasted Estimates, till 2035 (USD Billion)
Figure 19.1 Global Rare Kidney Disease Market: Distribution by Type of Biologics, 2024, 2030 and 2035 (USD Billion)
Figure 19.2 Rare Kidney Disease Market for Monoclonal Antibodies, Forecasted Estimates, till 2035 (USD Billion)
Figure 19.3 Rare Kidney Disease Market for Proteins, Forecasted Estimates, till 2035 (USD Billion)
Figure 20.1 Global Rare Kidney Disease Market: Distribution by Route of Administration, 2024, 2030 and 2035 (USD Billion)
Figure 20.2 Rare Kidney Disease Market for Oral, Forecasted Estimates, till 2035 (USD Billion)
Figure 20.3 Rare Kidney Disease Market for Intravenous, Forecasted Estimates, till 2035 (USD Billion)
Figure 20.4 Rare Kidney Disease Market for Subcutaneous, Forecasted Estimates, till 2035 (USD Billion)
Figure 20.5 Rare Kidney Disease Market for Others, Forecasted Estimates, till 2035 (USD Billion)
Figure 21.1 Global Rare Kidney Disease Market: Distribution by Type of Therapy, 2024, 2030 and 2035 (USD Billion)
Figure 21.2 Rare Kidney Disease Market for Monotherapy, Forecasted Estimates, till 2035 (USD Billion)
Figure 21.3 Rare Kidney Disease Market for Combination Therapy, Forecasted Estimates, till 2035 (USD Billion)
Figure 22.1 Global Rare Kidney Disease Market: Distribution by Key Geographical Regions, 2024, 2030 and 2035 (USD Billion)
Figure 22.2 Rare Kidney Disease Market in North America, Forecasted Estimates, till 2035 (USD Billion)
Figure 22.3 Rare Kidney Disease Market in Europe, Forecasted Estimates, till 2035 (USD Billion)
Figure 22.4 Rare Kidney Disease Market in Asia-Pacific, Forecasted Estimates, till 2035 (USD Billion)
Figure 22.5 Rare Kidney Disease Market in Rest of the World, Forecasted Estimates, till 2035 (USD Billion)
Figure 23.1 Approved Rare Kidney Disease Therapies Market, Agalsidase Beta BS I.V. Infusion / Agalsidase beta / JR-051 Sales Forecast, till 2035 (USD Million)
Figure 23.2 Approved Rare Kidney Disease Therapies Market, Benlysta® / Belimumab Sales Forecast, till 2035 (USD Million)
Figure 23.3 Approved Rare Kidney Disease Therapies Market, Elfabrio® / PRX-102 / Pegunigalsidase Alfa Sales Forecast, till 2035 (USD Million)
Figure 23.4 Approved Rare Kidney Disease Therapies Market, FILSPARI® / Sparsentan / RE-021 Sales Forecast, till 2035 (USD Million)
Figure 23.5 Approved Rare Kidney Disease Therapies Market, Galafold / Migalastat / AT1001 Sales Forecast, till 2035 (USD Million)
Figure 23.6 Approved Rare Kidney Disease Therapies Market, LUPKYNIS® / Voclosporin Sales Forecast, till 2035 (USD Million)
Figure 23.7 Approved Rare Kidney Disease Therapies Market, Sibnayal® / ADV7103 Sales Forecast, till 2035 (USD Million)
Figure 23.8 Approved Rare Kidney Disease Therapies Market, Tarpeyo® / Nef-301 / Nefigard-OLE / Nefecon / Kinpeygo Sales Forecast, till 2035 (USD Million)
Figure 23.9 Approved Rare Kidney Disease Therapies Market TERLIVAZ® / Terlipressin Sales Forecast, till 2035 (USD Million)
Figure 23.10 Approved Rare Kidney Disease Therapies Market Tolvaptan / Jynarque / Samsca / OPC-156 Sales Forecast, till 2035 (USD Million)
Figure 23.11 Approved Rare Kidney Disease Therapies Market ULTOMIRIS® / Ravulizumab-cwvz Sales Forecast, till 2035 (USD Million)
Figure 23.12 Phase III Rare Kidney Disease Therapies Market APL-2 / Pegcetacoplan/ Aspaveli / EMPAVELI / SYFOVRE Sales Forecast, till 2035 (USD Million)
Figure 23.13 Phase III Rare Kidney Disease Therapies Market Atacicept / VT-001 Sales Forecast, till 2035 (USD Million)
Figure 23.14 Phase III Rare Kidney Disease Therapies Market Atrasentan / CHK-01 / Atrasentan Hydrochloride / ABT-627 / Xinlay Sales Forecast, till 2035 (USD Million)
Figure 23.15 Phase III Rare Kidney Disease Therapies Market FILSPARI® / Sparsentan / RE-021 Sales Forecast, till 2035 (USD Million)
Figure 23.16 Phase III Rare Kidney Disease Therapies Market IONIS-FB-LRX / RO-7434656 / ASO Factor B / ISIS-696844 / RG62 Sales Forecast, till 2035 (USD Million)
Figure 23.17 Phase III Rare Kidney Disease Therapies Market Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast, till 2035 (USD Million)
Figure 23.18 Phase III Rare Kidney Disease Therapies Market Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast, till 2035 (USD Million)
Figure 23.19 Phase III Rare Kidney Disease Therapies Market Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast, till 2035 (USD Million)
Figure 23.20 Phase III Rare Kidney Disease Therapies Market Lucerastat / ACT 434964 / OGT 923 Sales Forecast, till 2035 (USD Million)
Figure 23.21 Phase III Rare Kidney Disease Therapies MIL62 Sales Forecast, till 2035 (USD Million)
Figure 23.22 Phase III Rare Kidney Disease Therapies Obinutuzumab / Afutuzumab / GA101 / Gazyva / RO5072759 Sales Forecast, till 2035 (USD Million)
Figure 23.23 Phase III Rare Kidney Disease Therapies Obinutuzumab / Afutuzumab / GA101 / Gazyva / RO5072759 Sales Forecast, till 2035 (USD Million)
Figure 23.24 Phase III Rare Kidney Disease Therapies Repagermanium / DMX-200 Sales Forecast, till 2035 (USD Million)
Figure 23.25 Phase III Rare Kidney Disease Therapies Market Sibeprenlimab / VIS-649 Sales Forecast, till 2035 (USD Million)
Figure 23.26 Phase III Rare Kidney Disease Therapies Market SNP-ACTH / SNP ACTH (1-39) Sales Forecast, till 2035 (USD Million)
Figure 23.27 Phase III Rare Kidney Disease Therapies Market Telitacicept / RC18 Sales Forecast, till 2035 (USD Million)
Figure 23.28 Phase III Rare Kidney Disease Therapies Market Tolvaptan / Jynarque / Samsca / OPC-156 Sales Forecast, till 2035 (USD Million)
Figure 23.29 Phase III Rare Kidney Disease Therapies Market Venglustat / Ibiglustat / GZ402671 Sales Forecast, till 2035 (USD Million)
Figure 24.1 Rare Kidney Disease Market: Distribution by Leading Drug Developers (based on sales of rare kidney disease therapies in the year 2024 (USD Million)
Figure 24.2 Rare Kidney Disease Market: Distribution by Leading Drug Developers (based on sales of rare kidney disease therapies in the year 2035 (USD Million)